Enanta Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 145
- Market Cap
- $275.6M
- Introduction
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also con...
A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 29
- Registration Number
- NCT03207425
- Locations
- π¨πΏ
Pharmaceuticals Research Associates, Prague, Czechia
πΊπΈAmerican Research Corporation at The Texas Liver Institute, San Antonio, Texas, United States
πΈπ°Summit SRO, Bratislava, Slovakia
Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.
- Conditions
- Interventions
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT03187496
- Locations
- πΊπΈ
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States
A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 146
- Registration Number
- NCT02918929
- Locations
- πΊπΈ
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States
EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 100
- Registration Number
- NCT02652377
- Locations
- π³πΏ
Auckland Clinical Studies Ltd, Auckland, New Zealand
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788
- First Posted Date
- 2014-10-03
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 16
- Registration Number
- NCT02255968
- Locations
- πΊπΈ
PPD Phase 1 Clinic, Austin, Texas, United States
Two-way Interaction Between Alisporivir and EDP239
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 42
- Registration Number
- NCT02173574
- Locations
- π©πͺ
Investigative Site, Berlin, Germany
Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 80
- Registration Number
- NCT01999725
- Locations
- πΊπΈ
PPD Phase I Clinic, Austin, Texas, United States
Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 28
- Registration Number
- NCT01856426
- Locations
- π©πͺ
Investigative Site, Hamburg, Germany
Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2009-10-08
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 52
- Registration Number
- NCT00990145
- Locations
- πΊπΈ
PPD Phase I Unit, Austin, Texas, United States
Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers
- Conditions
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2009-10-06
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 67
- Registration Number
- NCT00989872
- Locations
- πΊπΈ
PPD Phase I Unit, Austin, Texas, United States